Cargando…

An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria

BACKGROUND: The FIDELIO-DKD and FIGARO-DKD randomized clinical trials (RCTs) showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), reduced the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bramlage, Peter, Lanzinger, Stefanie, Mühldorfer, Steffen, Milek, Karsten, Gillessen, Anton, Veith, Roman, Ohde, Tobias, Danne, Thomas, Holl, Reinhard W., Seufert, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169333/ https://www.ncbi.nlm.nih.gov/pubmed/37158855 http://dx.doi.org/10.1186/s12933-023-01840-5

Ejemplares similares

Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases
por: van Mark, Gesine, et al.
Publicado: (2019)

Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries
por: Hartmann, Bettina, et al.
Publicado: (2017)

Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases
por: Bramlage, Peter, et al.
Publicado: (2019)

The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
por: Bramlage, Peter, et al.
Publicado: (2020)

Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases
por: van Mark, Gesine, et al.
Publicado: (2020)

DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus
por: van Mark, Gesine, et al.
Publicado: (2021)

Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry
por: Bramlage, Peter, et al.
Publicado: (2017)

Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
por: Danne, Thomas, et al.
Publicado: (2015)

Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis
por: Bramlage, Peter, et al.
Publicado: (2021)

Frequency and characteristics of diabetes in lipodystrophies and insulin receptoropathies compared with type 1 and type 2: results from the multicenter DPV registry
por: Kamrath, Clemens, et al.
Publicado: (2023)

Characterisation and clinical outcomes in children and adolescents with diabetes according to newly defined subgroups: a cohort study from the DPV registry
por: Warncke, Katharina, et al.
Publicado: (2023)

Renal function deterioration in adult patients with type-2 diabetes
por: Bramlage, Peter, et al.
Publicado: (2020)

Corrigendum to “Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases”
Publicado: (2020)

Size matters: Influence of center size on quality of diabetes control in children and adolescents with type 1 diabetes—A longitudinal analysis of the DPV cohort
por: Hackl, Lukas, et al.
Publicado: (2021)

Impact of Maternal Country of Birth on Type-1-Diabetes Therapy and Outcome in 27,643 Children and Adolescents from the DPV Registry
por: Scheuing, Nicole, et al.
Publicado: (2015)

Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database
por: Hammes, Hans-Peter, et al.
Publicado: (2015)

Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database
por: Welters, Alena, et al.
Publicado: (2020)

Prevalence of type 1 and type 2 diabetes in children and adolescents in Germany from 2002 to 2020: A study based on electronic health record data from the DPV registry
por: Stahl‐Pehe, Anna, et al.
Publicado: (2022)

Changes in cardiovascular risk factors among children and young adults with type 1 diabetes during the COVID‐19 pandemic compared to previous years—Results from the German DPV registry
por: Eckert, Alexander J., et al.
Publicado: (2023)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
por: Chiu, Nicholas, et al.
Publicado: (2022)

Type 1 diabetes mellitus and SARS‐CoV‐2 in pediatric and adult patients – Data from the DPV network
por: Büttner, Bastian Raphael, et al.
Publicado: (2022)

Polyendocrinopathy in Children, Adolescents, and Young Adults With Type 1 Diabetes: A multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database
por: Warncke, Katharina, et al.
Publicado: (2010)

Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis
por: Bohn, Barbara, et al.
Publicado: (2016)

Metabolic control during the first two years of the COVID-19 pandemic in pediatric patients with type 1 diabetes: results from the German DPV initiative
por: Hammersen, Johanna, et al.
Publicado: (2023)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative
por: DeSalvo, Daniel J., et al.
Publicado: (2018)

Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries
por: Lyons, Sarah K., et al.
Publicado: (2017)

La dirección por valores (DpV) : el cambio más alla de la dirección por objetivos /
por: García, Salvador
Publicado: (1997)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study
por: Seufert, Jochen, et al.
Publicado: (2013)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Immunofluorescence Analysis of Duck plague virus gE protein on DPV-infected ducks
por: Chang, Hua, et al.
Publicado: (2011)

Decentralization with PROFIBUS DP/DPV1: architecture and fundamentals, configuration and use with SIMATIC S7
por: Weigmann, Josef, et al.
Publicado: (2003)

Types of diabetes are not limited to age groups: type 1 diabetes in adults and type 2 diabetes in children and adolescents
por: Rosenbauer, Joachim, et al.
Publicado: (2019)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ev76rf75k5cuheeu0o3ikp60fe